

How I treat autoimmune hemolytic anemia

Ronald S. Go,¹ Jeffrey L. Winters,² and Neil E. Kay¹

¹Division of Hematology, Department of Medicine, and ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

Autoimmune hemolytic anemia (AIHA) is an uncommon entity that presents diagnostic, prognostic, and therapeutic dilemmas despite being a well-recognized entity for over 150 years. This is because of significant differences in the rates of hemolysis and associated diseases and because there is considerable clinical heterogeneity. In addition, there is a lack of clinical trials required to refine and update standardized and evidence-based

therapeutic approaches. To aid the clinician in AIHA management, we present four vignettes that represent and highlight distinct clinical presentations with separate diagnostic and therapeutic pathways that we use in our clinical practice setting. We also review the parameters present in diagnostic testing that allow for prognostic insight and present algorithms for both diagnosis and treatment of the AIHA patient in diverse situations. This is done

in the hope that this review may offer guidance in regard to personalized therapy recommendations. A section is included for the diagnosis of suspected AIHA with negative test results, a relatively infrequent but challenging situation, in order to assist in the overall evaluation spectrum for these patients. (*Blood*. 2017; 129(22):2971-2979)

Introduction and history

The diagnosis, prognosis, and management of autoimmune hemolytic anemia (AIHA) continue to be challenging in current practice. This is related to an incomplete understanding of the pathophysiology of the disease process, complexity of initiating factors, and a lack of evidence-based standardized therapies. There is no completely validated and standard therapeutic approach to AIHA, because randomized clinical trials are difficult to implement.

Key historical events of AIHA include original descriptions of an AIHA-like disease in the 19th century and subsequently more definitive descriptions in the seminal publications of J. Donath and K. L and steiner in the early 20th century.¹⁻⁴ The direct antiglobulin test (DAT) was described by Robin Coombs and A. Mourant in 1945 and is a laboratory-based assay still of great utility in the diagnosis of AIHA.⁵ A positive DAT result, along with no other obvious cause of hemolysis, is the defining clinical signature of AIHA. Antibodies directed against self-erythrocytes capable of induction of hemolysis at excessive or uncompensated rates result in an entity known as AIHA. These antibodies are usually immunoglobulin G (IgG) in nature, capable of fixing complement, and are detected by the DAT. The DAT is based on specific antibodies to IgG and/or C3d (fragment of the third component of complement) capable of binding to these components on the erythrocyte surface. If the latter molecules are present in sufficient quantity on the erythrocyte membrane, the result is a visible agglutination by cross-linking erythrocytes. DAT techniques that enhance the sensitivity of this test beyond visual agglutination have been developed but are not routinely used. If more commonly employed, these enhanced tests would increase the detection of autoantibodies but are likely to lead to questions about their exact relationship to clinically important disease. These tests are important in the setting of DAT-negative AIHA, an uncommon form of AIHA (see case 4). In contrast to the DAT, the indirect antiglobulin (indirect Coombs) test is used to detect erythrocyte antibodies in patient serum. This is done by incubating patient serum with a panel of erythrocytes of known antigens and observing whether agglutination

results. The “super-Coombs” test is an enhanced direct Coombs test that utilizes different methods to generate erythrocyte agglutination (also reviewed in Table 4 below) and performed when the standard DAT result is negative.

The incidence of AIHA is considered uncommon, with prior estimates of 1 to 3 in 100 000 population annually.⁶ AIHA affecting children and adults and warm-reacting antibodies are the primary pathogenic etiology in the majority of cases (~75% and ~90%, respectively).^{7,8} AIHA can be subdivided into warm- or cold-mediated disease based on the thermal optimum used to detect anti-erythrocyte antibodies. Primary AIHA comprises ~50% of cases, while secondary AIHA is usually associated with B-cell malignancies, autoimmune diseases, or drugs. Primary (idiopathic) AIHA occurs when no disease is clearly associated with the hemolysis, whereas secondary AIHA occurs when hemolytic anemia is directly associated with another disease or drug believed to induce or promote the hemolysis. The progression of events that need to be dealt with in the management of AIHA includes using the appropriate methodologies for diagnosing AIHA, defining whether AIHA is primary or secondary in type, and identifying the most effective treatment for a given patient.⁹

Serology that matters in warm AIHA (WAIHA) and cold agglutinin disease (CAD) evaluation

The essence of AIHA is that it is caused by the increased destruction of erythrocytes by anti-erythrocyte autoantibodies. This can occur with or without complement fixation and activation. Here is a primer for the clinician to aid in the fundamental understanding of immune mediators in AIHA, diagnosis, and prognostic risk.

Advances in understanding the pathophysiology of AIHA and how to use anti-CD20 antibodies with or without immunosuppressive agents has augmented treatment approaches.

Submitted 28 November 2016; accepted 21 March 2017. Prepublished online as *Blood* First Edition paper, 30 March 2017; DOI 10.1182/blood-2016-11-693689.

© 2017 by The American Society of Hematology

Figure 1 shows the pattern of antibodies and complement that are typically found on erythrocyte membranes in warm and CAD AIHA.¹⁰⁻¹³ It features the most well-characterized erythrocyte antigens involved in AIHA and the more typical diseases or drugs associated with specific AIHA subtypes. These autoantibodies can be of IgG, IgM, or IgA isotypes, but most commonly, the antibody is an IgG antibody in WAIHA and an IgM antibody in CAD. The IgA isotype is much less commonly involved in AIHA but may cause severe hemolysis.^{14,15} The ability of the anti-erythrocyte antibody to bind to the erythrocyte antigen at specific temperatures is fundamental to the diagnosis in terms of whether it is designated as warm (reacts maximally at 37°C) or cold (reacts maximally at <4°C) AIHA. The pathologic and clinical features of AIHA relate to the autoantibody class, thermal amplitude, and their efficiency in activating complement. It is known that the broader the thermal amplitude, the worse the rate of hemolysis for IgM cold agglutinins. With initiation of therapy, it is best to monitor restoration of the hemoglobin and reticulocyte levels over the first several weeks of therapy. Monitoring the DAT is routine, but even if the result remains positive, this may not reflect a lack of disease control. The extent of hemolysis must be matched by a robust marrow-based erythrocyte production rate but may be insufficient.^{16,17} Insufficient reticulocytosis may occur in children and in adults with very severe hemolysis. Recognition of this phenomenon has generated data indicating that the use of erythropoietin may be useful in managing situations like this and refractory AIHA.¹⁸

Case 1: idiopathic WAIHA

A 68-year-old previously healthy woman presented with new-onset fatigue. Physical examination was remarkable only for mild pallor. Laboratory test results (with reference ranges provided in brackets) were significant for hemoglobin (9.3 g/dL [12.0-15.5]), mean cell volume (MCV; 89.7 fL [81.6-98.3]), absolute reticulocyte count ($119 \times 10^9/L$ [38.1-112.6]), haptoglobin (<14 mg/dL [30-200]), lactate dehydrogenase (LDH; 267 U/L [122-222]), total bilirubin (0.8 mg/dL [0.1-1]), and blood smear showing polychromasia. The DAT showed 2+ anti-IgG and weakly positive anti-C3.

Should we routinely evaluate for an underlying lymphoid malignancy?

Contemporary series composed of unselected patients with WAIHA are scarce. A recent single-institutional study (N = 60) showed that an underlying condition could be found in 48% of patients at or preceding the diagnosis and in another 8% subsequently. The most common conditions were lymphoma or undefined lymphoproliferative disorder (54%) and autoimmune diseases (27%).¹⁹ Another report (N = 107) studied warm and cold AIHA cases initially considered idiopathic or associated with autoimmune disorders and found that 18% of patients developed lymphoma at a median of 27 months.²⁰ In both studies, evaluation for lymphoma was not routinely performed at the time of AIHA diagnosis. Therefore, the prevalence of lymphoma is likely to be underestimated. It is reasonable to consider evaluating for lymphoid malignancies, including a computed tomographic scan of the chest, abdomen, and pelvis, as well as bone marrow biopsy in patients with newly diagnosed AIHA. Discovery of such malignancies upfront may open the option of non-glucocorticoid-based therapies, improve the chance of response, and minimize relapses.

How do we use glucocorticoids?

While glucocorticoids are considered the first-line treatment in WAIHA, this was empirically derived. Mechanisms of actions include suppression of autoantibody production, reduction in autoantibody affinity, and decreased destruction of erythrocytes by splenic macrophages, perhaps by diminished expression of Fc γ receptors.^{21,22} The first-ever randomized trial of newly diagnosed AIHA compared high-dose prednisone (1.5 mg/kg per day \times 2 weeks, then tapered over 8-12 weeks), with or without rituximab, found that 50% of patients in the prednisone-only group achieved either a complete response (CR) or partial response (PR) at 3 months. However, nearly half of the responders relapsed within a year. This study was limited by small sample size (N = 64) and did not report the proportion of patients needing second-line treatment after relapse. The rituximab arm had higher rates of CR at 12 months (75% vs 36%) and relapse-free survival at 36 months (70% vs 45%).²³ A prospective registry study of 308 patients showed a higher prednisone-based response rate of 80%. Half did not require subsequent treatment after a median follow-up of 33 months.²⁴ The optimal starting dose and taper schedule of prednisone are unknown, although most reports and experts use starting doses of 1.0 to 1.5 mg/kg per day or a flat dose of 60 to 100 mg daily.²⁵⁻²⁷ The starting dose is maintained for at least 2 weeks and until achievement of hemoglobin >12 g/dL. Thereafter, we taper the prednisone by 20 mg every week until a dose of 20 mg daily is reached, followed by a slower taper over 4 to 8 weeks. We monitor hemoglobin levels on a weekly basis until the tapering process is complete. Thereafter, less frequent testing is needed. The success of high-dose dexamethasone (40 mg daily for 4 days) in the initial treatment of immune thrombocytopenia makes an attractive alternative option in the treatment of WAIHA, although further studies are needed.²⁸ One study showed its efficacy in the setting of refractory AIHA.²⁹ Because chronic hemolysis may potentially lead to folate deficiency due to increased utilization, it is customary to supplement with 1 mg folic acid daily when glucocorticoid is started.

What is the value of splenectomy?

Splenectomy is effective but has never been compared with other treatments in the second-line setting. The response rate of splenectomy in unselected patients is ~60% to 90%, and approximately one-third will relapse, mostly within 1 to 2 months.^{24,30,31} Patients without an underlying autoimmune disease or hematologic malignancy are twice as likely to respond as those with such conditions (82% vs 19% complete response).³² Although rituximab has increasingly superseded splenectomy in recent retrospective studies and may be primary second line for some centers,³³ we still consider splenectomy as the primary second-line option in idiopathic AIHA. In one study of 52 patients with AIHA, 64% were in unmaintained remission after a mean follow-up of 33 months. Relapse patterns were not reported separately for idiopathic and secondary AIHAs.³⁰ For those with underlying medical conditions, alternative treatments such as rituximab and disease-specific therapies may be a better next option. It is absolutely essential to vaccinate against encapsulated bacterial organisms at least 14 days prior to (preferable) or at least 14 days after splenectomy to maximize immunity.³⁴

How do we treat subsequent relapse or refractory disease?

With no standard definition for treatment responses reflecting refractory or relapsed AIHA, the definition proposed by Barcellini et al is useful.³⁵ We consider a subsequent line of treatment in the following scenarios: (1) requirement of >20 mg of prednisone daily (or equivalent corticosteroid) to maintain hemolysis control; (2) clinically significant




Figure 1. Direct antiglobulin test serology and clinical aspects. Shown are the spectrum of DAT serologic findings, autoimmune hemolytic classifications, antigen specificity, and medical/drug associations.^{10,11} Drugs most commonly implicated^{11-13,20} in drug-induced autoimmune hemolytic anemia are β lactam antibiotics (penicillin, ceftriaxone, cefotetan, and piperacillin), nonsteroidal anti-inflammatory drugs (tolmetin, sulindac, and diclofenac), quinine, purine nucleoside analogs (fludarabine and cladribine), and platinum (cisplatin and oxaliplatin).^{12,13}

relapse (hemoglobin < 11g/dL or symptomatic anemia with ongoing evidence of hemolysis); or (3) intolerance to a currently effective treatment. If hemolysis continues that is well compensated after prednisone tapering, starting a second-line treatment may not be necessary. Similarly, DAT negativity is not essential with controlled hemolysis. The more commonly used treatments along with their corresponding dosing schedules are displayed in Table 1.³⁶⁻⁴² Patterns of care studies are not available, but single-agent rituximab is perhaps the most commonly used treatment in this setting and is our first choice after splenectomy relapse. In a meta-analysis of 21 studies that investigated rituximab, the overall response (OR) and CR rates were 79% and 42%, respectively. The OR was similar regardless of whether it was idiopathic or secondary AIHA (67% vs 72%).⁴³ In studies with >3 years of follow-up, the relapse rate was ~50%. However, most patients responded to rituximab retreatment.^{19,44}

Information about response rates and their duration for less used drugs often varied and were frequently not reported. Many of these treatments were added to corticosteroids at relapse. It is impossible to determine the comparative efficacy of these treatments. We caution the treatment outcomes in Table 1 may look more optimistic due to reporting bias and small study sample sizes. The choice of treatment beyond rituximab will depend on the physician's clinical judgment, the patient's preference, and the drug's side effect profile.

In our experience using noncorticosteroid immunosuppressive agents, the response may take months to be evident. Therefore, it is reasonable continue treatment of at least 8 to 12 weeks, especially if the hemolysis rate is stable during treatment. A recent review article has more in-depth discussions of the individual treatment options for relapsed or refractory disease.²⁶

Case 2: WAIHA associated with chronic lymphocytic leukemia (CLL)

A 62-year old male with a history of CLL presented with profound fatigue. He was severely anemic with hemoglobin of 5.8 g/dL. Additional laboratory test results (with reference ranges in parentheses) included MCV 93.5 fL, white cell count $4.0 \times 10^9/L$ (3.5-10.5), platelet count $50 \times 10^9/L$ (150-450), absolute lymphocyte count $1.6 \times 10^9/L$ (0.9-2.9), absolute reticulocyte count $10 \times 10^9/L$, haptoglobin <14 mg/dL, LDH 420 U/L, total bilirubin 2.0 mg/dL, indirect bilirubin 1.5 mg/dL (<1.0), and blood smear showing polychromasia. DAT showed 2+ anti-IgG and no anti-C3. He was treated a year ago with a fludarabine/cyclophosphamide/rituximab combination regimen and achieved a PR.

Table 1. Pharmacologic treatment options for relapsed or refractory warm autoimmune hemolytic anemia from a case series

Treatment	Initial dose(s)	OR, %	Median time to response (range)	Median response duration (range)	Relapse rate (at 1-2 y), %	Comments	Reference
Azathioprine	2-4 mg/kg orally once a day	50-70	NA	11 mo (4-36)	60	N = 9-31	19, 24, 36, 37
Cyclophosphamide (low dose)	1-2 mg/kg orally once a day; or 50-150 mg orally once a day	50-70	NA	11 mo (4-36)	50	N = 7-40	19, 24, 26, 37
Cyclophosphamide (high dose)	50 mg/kg IV days 1-4 with mesna and granulocyte colony stimulating factor rescue; or 1000 mg IV every 4 wk × 4	100	3 wk; 82% at 4 mo	15 mo (4-29)	0	For the 50 mg/kg dose, 40% hospitalization due to complications (N = 9-17)	38, 39
Cyclosporine	2.5 mg/kg orally twice a day	60	NA	11 mo (4-36)	NA	Maintain serum level 200-400 ng/mL (N = 12)	24
Danazol	200 mg orally 3-4 times daily	60-80	NA	18 mo (7-77)	30-75	Maintenance dose 200-400 mg/day (N = 15-22)	8, 40, 41
Mycophenolate	500-1000 mg orally twice a day	25-70	5 mo (1-9)	11 mo (4-36)	NA	N = 3-4	19, 24, 42
Rituximab	375 mg/m ² IV every week × 4; or 100 mg IV every week × 2-4	70-90	2 wk (1-12)	20 mo (9-60)	20-50	N = 25-74	19, 24, 44

NA, not available.

When is erythrocyte transfusion indicated OR contraindicated, and what needs to be considered when transfusing a patient?

Consideration of erythrocyte transfusion for hemodynamically stable patients with a hemoglobin of <7 g/dL is based on the AABB guidelines.⁴⁵ This restrictive strategy applies to the relatively asymptomatic patient. For patients who are experiencing cardiopulmonary symptoms due to anemia, erythrocyte transfusion should not be withheld regardless of hemoglobin level. Because the major erythrocyte antigenic targets of the autoantibodies (Rh, Rh-related, band 3, or glycophorin) are nearly universally present in humans,²⁷ special compatibility test procedures are necessary to rule out the presence of an alloantibody and proper crossmatching. These tests include removing the autoantibody from the patient's serum, leaving behind any alloantibodies by utilizing either the patient's (autologous) red blood cells or selected sets of donor red blood cells of known antigen type to adsorb the autoantibody. The adsorbed serum (adsorbate) is then used to identify any potential allogeneic antibodies by reacting it against panels of red blood cells of known antigen type (antibody screen) and to perform crossmatching to identify compatible erythrocytes. In severe anemia, there may be insufficient autologous erythrocytes to perform an autologous adsorption. To enhance the safety of transfused erythrocytes, it is possible to use erythrocytes phenotypically matched with the patient. This means determining the antigen profile of the patient's erythrocytes using typing sera for antigens toward common alloantibodies. Antigen typing of the patient's erythrocytes should be performed prior to transfusion or at least 3 months after the patient's last transfusion to avoid potential inaccurate typing. Determining the "molecular phenotype" of a patient in order to provide antigen matched red blood cells is possible and can be used in transfused patients.

While phenotyping and providing phenotypically matched erythrocytes reduces the risk of hemolysis due to alloantibodies "hiding behind" an autoantibody, it does not eliminate it. More than 400 red cell antigens have been identified, and typing sera are available for a minority. Molecular phenotyping may also fail to correctly determine a patient's antigen type because of gene silencing through mutations occurring outside of antigen coding regions. The presence of these other methods means that immediate discussion with the blood bank personnel is necessary to avoid delays or miscommunication and allow for timely testing. It is expected that the transfused erythrocytes, even if phenotypically matched, will have shorter half-lives. Nevertheless,

there is no absolute contraindication to erythrocyte transfusion, as it remains a safe procedure.

Do we treat the CLL or AIHA or both?

We first determine whether there is an indication for the treatment of CLL based on the International Workshop on CLL guidelines for active disease.⁴⁶ If chemotherapy is indicated, then any of the nonpurine nucleoside analog containing chemoimmunotherapy combinations or ibrutinib may be used, since they are not known to be associated with or cause hemolysis.⁴⁷ The AIHA generally responds in parallel to CLL therapy. Otherwise, the treatment is similar to what is used for AIHA in the nonmalignant setting.

How commonly does AIHA occur during fludarabine treatment?

The incidence of AIHA among previously untreated patients receiving nonpurine nucleoside analog based treatment is ~2%.⁴⁸ This contrasts with the ~6% incidence among those receiving fludarabine-based therapy.⁴⁹⁻⁵¹ In the latter group, the majority of cases occur during the first 3 treatment cycles, although AIHA can occur at any time during treatment and reoccur after rechallenge. Hemolytic episodes can be severe enough to require transfusion, and fatalities have been reported.⁵² One randomized trial showed that the combination of fludarabine and cyclophosphamide might have a lower incidence of AIHA than fludarabine alone.⁵⁰ However, this was not supported by other randomized trials.^{49,51} In another randomized trial, the incidence of AIHA was similar (~1%) among those who received fludarabine and cyclophosphamide with or without rituximab.⁵³ Thus, we generally discontinue fludarabine-based therapies in the setting of AIHA, especially when the hemolysis is severe. Purine nucleoside analogs such as pentostatin and cladribine are also associated with AIHA and should be avoided.^{54,55} If further chemotherapy is unnecessary, we use corticosteroids alone. If additional CLL treatment is needed, we prefer rituximab/cyclophosphamide/dexamethasone, bendamustine/rituximab, or novel signal inhibitors because of their safety in this setting.⁵⁶⁻⁵⁹ These 2 chemotherapy combination regimens have been shown to effectively treat steroid-refractory AIHA. In most (>80%) of the cases, there was sustained control of hemolysis and CLL.^{58,59} Among those who were receiving AIHA treatment, the initiation of ibrutinib frequently allowed discontinuation of AIHA treatment within 5 months.⁴⁷

Table 2. Pharmacologic treatment options for relapsed or refractory cold agglutinin disease from case series

Treatment	Initial dose	OR, %	Median time To response (range)	Median response duration (range)	Relapse rate (at 1-2 y), %	Comments	Reference
Chlorambucil	4-20 mg orally once a day	16-46	NA	11 mo	NA	Included newly diagnosed and previously treated patients (N = 19-37)	64, 65
Cyclophosphamide	50-150 mg orally once a day						
Rituximab	375 mg/m ² IV every week × 4 wk	45-54	1.5 mo (1-2)	10 mo (8-27)	50-83	Included newly diagnosed and previously treated patients (N = 20-32)	64, 67, 68
Rituximab + prednisone	Rituximab: 100 mg IV every week × 4 wk; Prednisone: 1 mg/kg per day orally × 30 d, then taper	56	2 wk	NA	33	Included newly diagnosed and previously treated patients (N = 19)	35
Rituximab + fludarabine	Rituximab: 375 mg/m ² IV every 4 wk; Fludarabine: 40 mg/m ² orally on days 1-5 every 4 wk; both × 4 cycles	76	4 mo	>66 mo (3-66)	23	Grade 3-4 hematologic toxicities in 41% (N = 29)	73

NA, not available.

Are any of the recently approved CLL drugs associated with AIHA?

Five drugs have been recently approved for use in CLL: ibrutinib, idelalisib, obinutuzumab, ofatumumab, and venetoclax. There is no evidence from randomized trials to suggest that any of these agents increases the absolute risk of AIHA.^{48,60-62} There is a flare phenomenon described among patients with preexisting immune cytopenias treated with ibrutinib.⁵⁷ Immune cytopenia may exacerbate shortly after starting ibrutinib (within a median of 3 weeks and ranging from 2 to 8 weeks). The flare episode can be managed by continuation of ibrutinib with or without the addition of corticosteroids.⁵⁷

Case 3: CAD

A 54-year-old man with acute bronchitis was treated with azithromycin with resolution of respiratory symptoms. Because of continued fatigue, laboratory tests were performed, which showed hemoglobin 11.4 g/dL, MCV 100 fL, absolute reticulocyte count $266 \times 10^9/L$, haptoglobin <14 mg/dL, LDH 295 U/L, total bilirubin 1.3 mg/dL, and indirect bilirubin 1.0 mg/dL; the blood smear showed erythrocyte agglutination. DAT showed weak+ anti-IgG and 3+ anti-C3. Serum protein

Table 3. Mechanisms involved in DAT-negative WAIHA

1. Erythrocyte-bound antibody below the limit of detection of standard DAT
Erythrocytes from healthy individuals have up to 35 molecules of IgG bound to their surface.
Standard DAT can detect >300-500 bound IgG molecules.
WAIHA can occur with as few as 70-434 bound IgG molecules.
2. Low-affinity IgG antibodies
Loosely bound antibodies are dislodged during the washing of erythrocytes or when samples are left standing at room temperature.
3. IgA antibodies
IgA antibodies may trigger phagocytosis and antibody-dependent cell cytotoxicity, resulting in hemolysis.
Standard anti-human globulin reagents do not have anti-IgA activity, as most polyspecific reagents contain a mixture of monoclonal anti-IgG and anti-C3d.
4. Warm-reacting IgM and monomeric IgM antibodies
IgM antibodies reacting at warm temperatures and monomeric IgM may not fix complement.
Standard anti-human globulin reagents do not detect IgM. However, these antibodies will detect C3d if the IgM antibody fixes complement.

electrophoresis showed a small, unquantifiable amount of IgM κ monoclonal protein, while *Mycoplasma pneumoniae* serology was consistent with past exposure. Cold agglutinin titer was >512. Physical examination was unremarkable.

What should be the extent of workup for a hematologic malignancy at the time of diagnosis?

In half of the cases, an autoimmune condition or infection (*M pneumoniae* or Epstein-Barr virus) are identified as potential precipitating factors.⁶³ In the remainder, CAD is commonly associated with an underlying clonal B-cell disorder similar to WAIHA. In a recent series of non-infection-related CAD patients (N = 89), 34% were found to have a B-cell lymphoma, and another 47% had monoclonal gammopathy of undetermined significance.⁶⁴ The predominant monoclonal protein was IgM κ (95%), while the rest was either IgG λ or IgA λ .⁶⁵ Therefore, a routine evaluation for non-Hodgkin lymphoma that includes bone marrow biopsy and body computed tomographic scan should be considered when there is no obvious infection.

Who should we treat?

Supportive measures aimed at avoiding cold exposures apply to all patients regardless of symptoms. Day-to-day practices include adequate clothing for cold weather, keeping indoor thermostat at higher set points, and avoidance of icy drinks and cold showers. If the patient is admitted due to a medical event or for surgery, the application of body-warming blankets and prewarming of IV fluids and blood products may minimize the exacerbation of the hemolysis. We consider systemic treatment when there are substantial or disabling signs or symptoms despite supportive measures. These include cold-induced manifestations such as acrocyanosis or Raynaud phenomenon and clinical sequelae of anemia and hemolysis. CAD associated with infections is usually self-limited and generally does not require treatment.⁶⁶ It is necessary to treat the underlying lymphoproliferative disorder if this is present.

What is the efficacy of rituximab?

Despite the lack of randomized trials, single-agent rituximab is currently considered the first-line systemic therapy for CAD due to its superior efficacy and tolerability. Two relatively larger prospective studies that included newly diagnosed and previously treated patients (N = 20 and N = 27) have shown ORs ranging from 45% to 54% with

Table 4. Enhanced DATs

Name	Description	DAT-negative WAIHA detected
Column agglutination	Erythrocytes are placed on a column of beads suspended in diluent containing anti-human globulin reagent and centrifuged. Agglutination of antibody-coated erythrocytes results in cells failing to migrate in the bottom of the column. No cell washing is required, as serum/plasma is retained on top of the column.	Low-affinity autoantibodies
4°C Low-ionic-strength saline wash	Erythrocytes are washed with cold, low-ionic-strength saline to avoid removal of low-affinity antibodies.	Low-affinity autoantibodies
Polybrene	Polybrene induces aggregation of erythrocytes, which are dispersed by sodium citrate. If antibody is present, erythrocytes will not disperse.	Erythrocyte-bound antibody below limit of detection of standard DAT
Flow cytometry	Erythrocytes incubated with anti-human globulin reagent are tagged with fluorescence and examined by flow cytometry. Anti-human globulin reagents to IgG, IgA, and IgM are used.	Erythrocyte-bound antibody below limit of detection of standard DAT IgA antibody Erythrocyte-bound IgM and monomeric IgM antibody
IgA	Anti-IgA is used instead of anti-IgG and anti-C3d.	IgA antibody
IgM	Anti-IgM is used instead of anti-IgG and anti-C3d.	IgM warm antibody and monomeric IgM

median times to response between 1 and 2 months and median response durations of 8 to 11 months. However, CRs were uncommon (<5%). The responses were similar regardless of the presence or absence of an underlying lymphoid malignancy.⁶⁷ Another prospective study (N = 19) used a combination of rituximab and prednisone and achieved a relatively shorter median time to response (2 weeks), more CRs (56%), and fewer relapses (33% at 12 months), suggesting a potential additive effect.³⁵ Both standard-dose (375 mg/m² IV weekly × 4) and low-dose (100 mg fixed dose IV weekly × 4) rituximab were effective.^{35,67,68}

Do corticosteroids work?

Older studies showed poor responses to corticosteroids (<15% OR),^{65,69} but recent studies suggest that corticosteroids are still commonly used and have higher response rates. In one study, corticosteroids were used in 24 of 89 patients (27%), mostly (81%) as first-line treatment, and produced an OR of 36%. One-third of patients did not require additional therapy after long-term follow-up.⁶⁴ Another study (N = 64) of patients receiving corticosteroids reported an OR of 69% (mostly PRs). Many patients had to be maintained on corticosteroids at higher doses compared with WAIHA patients.²⁴ In one of these two recent large series, half of the patients had predominantly IgG cold agglutinin.⁶⁴ Reports suggest long-term efficacy of corticosteroids in this latter subgroup.^{70,71}

What is the value of splenectomy?

Splenectomy is generally not recommended as a treatment in CAD, as erythrocyte destruction is known to primarily occur in the liver.⁷² In the 3 largest series of primary CAD reported in recent years (total N = 259), only 11 patients (4.2%) were treated with splenectomy, although, surprisingly, 3 (27.3%) responded with a response duration between 5 and 15 months.^{24,64,65} The antibody specificities of the DAT in these patients were not reported. There are anecdotal reports that some patients with predominantly IgG cold agglutinin may achieve a durable response to splenectomy.⁷⁰

How do we treat subsequent relapse or refractory disease?

Data on the efficacy of alternative systemic treatments are limited for CAD. A summary of case treatment series with reported efficacy in CAD are shown in Table 2.⁷³ While most immunosuppressive or cytotoxic agents used in WAIHA have been tested in CAD, the efficacy

is generally lower. Treatments reported to have nearly no response are azathioprine and cladribine.^{65,74} Treatments reported to be effective but published as single case reports are bortezomib, eculizumab, rituximab/bendamustine, rituximab/cyclophosphamide, and rituximab/fludarabine/cyclophosphamide.^{59,75-80}

Case 4: DAT-negative AIHA

A 50-year-old male presented with a 2-week history of fatigue and jaundice. He denied alcohol use, risk factors for viral hepatitis, recent travel, and toxin exposure, and he was not taking any medication. Physical examination showed icteric sclerae and hepatosplenomegaly. Further evaluation showed hemoglobin 6.0 g/dL, absolute reticulocyte count $272 \times 10^9/L$, platelet count $245 \times 10^9/L$, LDH 1000 U/L, haptoglobin <14 mg/dL, total bilirubin 6.3 mg/dL, indirect bilirubin 4.7 mg/dL, 2 negative DAT results, no paroxysmal hemoglobinuria clone, and blood smear with marked spherocytosis. Bone marrow biopsy specimen demonstrated erythroid hyperplasia. Due to worsening symptomatic anemia, he was transfused with 4 U erythrocytes, which raised the hemoglobin to 10.0 g/dL, but within 24 hours, hemoglobin declined to 7.5 g/dL. Because of the high index of suspicion for WAIHA, enhanced DATs were performed and detected a low-affinity IgG antibody.

How common is DAT-negative WAIHA?

A total of 3% to 11% of patients with hemolytic anemia clinically consistent with WAIHA will have a negative DAT result.^{81,82} A negative test result, considered critical for the diagnosis of WAIHA, may lead physicians to reject the diagnosis, resulting in additional patient evaluation and delays in treatment. It is therefore important to recognize the existence of DAT-negative WAIHA. The most common “cause” of DAT-negative WAIHA is technical. Approximately 10% to 50% of patients with DAT-negative WAIHA will have a positive standard DAT result using anti-IgG and anti-C3d reagents retested at immunohematology reference laboratories.^{81,83,84} If suspicion of WAIHA remains high, DAT should be repeated, preferably by an immunohematology reference laboratory. The presenting clinical features and treatment responses of patients with DAT-negative WAIHA are similar to those of patients with DAT-positive WAIHA.⁸⁵

How do we test for DAT-negative AIHA?

The identified mechanisms by which erythrocyte antibody escapes recognition by standard DAT are listed in Table 3.^{81,82} There are several “enhanced” DATs that can be performed to detect one or more of the described mechanisms. The more common enhanced DATs are shown in Table 4.^{81,82} No single enhanced DAT will detect all potential hemolytic mechanisms requiring a panel of tests.

Conclusion and challenges

The etiology of AIHA remains incompletely understood; however, the mechanisms of erythrocyte destruction and the clinical complications that accompany this disorder are well defined. The clinical heterogeneity of AIHA requires the clinician clearly define the nature of the disorder for each patient. In this article, we also emphasized approaches to AIHA where the DAT result is negative. The determination that the AIHA is warm or cold mediated does give significant insight into the potential clinical course and its management. We have provided the rationale and evidence basis for certain treatments and their relative hierarchy for use in the subtypes of AIHA. We have also highlighted the need to look for associated diseases, as their management may aid in AIHA therapy.

The usual options for treatment of warm-mediated AIHA with steroids with or without rituximab and or splenectomy can be considered to be standard practice and are very helpful in ~80% of cases. However, the upfront management of CAD is typically less successful and remains a challenge. Tables 1 and 2 list the treatment options for relapsed or refractory warm- and cold-mediated AIHA, respectively. There is no clear consensus on the sequence or timing of these agents, so additional studies are needed to improve efficacy in the

relapsed setting. Novel strategic therapies can be devised based on known pathophysiology that would improve on the decrease or removal of autoantibody production and/or reduce the phagocytosis of antibody/complement-coated erythrocytes. There is an ongoing phase 2 trial (NCT02612558) evaluating the use of a *syk* inhibitor, fostamatinib, in the therapy of refractory AIHA, a phase 3 trial of rituximab in upfront therapy of AIHA (NCT01181154), and a completed trial of low-dose rituximab plus prednisone (NCT01345708 and NCT00309881). Given the role of interaction of IgG with the Fc γ receptor [Fc γ R] or the neonatal Fc receptor [FcRn] in autoimmune disease, there is growing interest in blockade or modulation of these latter receptors with various formulations of intravenous immunoglobulin.⁸⁶ These trials and investigations show that novel agents are being tested in AIHA to enhance our effective therapeutic repertoire and should expand our therapeutic repertoire in the coming years.

Authorship

Contribution: R.S.G., J.L.W., and N.E.K. designed research, performed research, analyzed data, and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: R.S.G., 0000-0002-8284-3495; J.L.W., 0000-0001-8654-3732; N.E.K., 0000-0002-5951-5055.

Correspondence: Neil E. Kay, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: kay.neil@mayo.edu.

References

- Landsteiner K. Über Beziehungen zwischen dem Blutsrum und den Körperzellen. *Munch Med Wochenschr.* 1903;50:1812-1814.
- Donath JL. Über paroxysmale Hamoglobinurie. *Munch Med Wochenschr.* 1904;51:1590-1593.
- Allgood JW, Chaplin H Jr. Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965. *Am J Med.* 1967;43(2):254-273.
- Mack P, Freedman J. Autoimmune hemolytic anemia: a history. *Transfus Med Rev.* 2000; 14(3):223-233.
- Coombs RR, Mourant AE, Race RR. A new test for the detection of weak and incomplete Rh agglutinins. *Br J Exp Pathol.* 1945;26(4):255-266.
- Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. *J Autoimmun.* 2007;29(1): 1-9.
- Aladjidi N, Leverger G, Leblanc T, et al; Centre de Référence National des Cytopenies Auto-immunes de l'Enfant (CEREVANCE). New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. *Haematologica.* 2011;96(5): 655-663.
- Genty I, Michel M, Hermine O, Schaeffer A, Godeau B, Rochant H. [Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases]. *Rev Med Interne.* 2002;23(11):901-909.
- Crowther M, Chan YL, Garbett IK, Lim W, Vickers MA, Crowther MA. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. *Blood.* 2011;118(15):4036-4040.
- Fung M, Grossman BJ, Hillyer C, Westhoff CM. Technical Manual. 18th ed. Bethesda, MD: AABB Press; 2014.
- Arndt PA. Drug-induced immune hemolytic anemia: the last 30 years of changes. *Immunohematology.* 2014;30(2):44-54.
- Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. *Immunohematology.* 2014;30(2):66-79.
- Johnson ST, Fueger JT, Gottschall JL. One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia—a new paradigm. *Transfusion.* 2007; 47(4):697-702.
- Bardill B, Mengis C, Tschopp M, Willemin WA. Severe IgA-mediated auto-immune haemolytic anaemia in a 48-yr-old woman. *Eur J Haematol.* 2003;70(1):60-63.
- Sokol RJ, Booker DJ, Stamps R, Booth JR, Hook V. IgA red cell autoantibodies and autoimmune hemolysis. *Transfusion.* 1997;37(2):175-181.
- Conley CL, Lippman SM, Ness P. Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. *JAMA.* 1980;244(15): 1688-1690.
- Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. *Blood.* 1987;69(3):820-826.
- Arbach O, Funck R, Seibt F, Salama A. Erythropoietin may improve anemia in patients with autoimmune hemolytic anemia associated with reticulocytopenia. *Transfus Med Hemother.* 2012;39(3):221-223.
- Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. *Am J Hematol.* 2014;89(9): E150-E155.
- Sallah S, Wan JY, Hanrahan LR. Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia. *Clinical cancer research: an official journal of the American Association for Cancer Research.* 2001; 7(4):791-794.
- Rosse WF. Quantitative immunology of immune hemolytic anemia: II. The relationship of cell-bound antibody to hemolysis and the effect of treatment. *J Clin Invest.* 1971;50(4):734-743.
- Fries LF, Brickman CM, Frank MM. Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy. *J Immunol.* 1983;131(3): 1240-1245.
- Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. *Br J Haematol.* 2013;163(3): 393-399.
- Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. *Blood.* 2014; 124(19):2930-2936.
- Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults. *Blood.* 2010;116(11): 1831-1838.

26. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. *Haematologica*. 2014;99(10):1547-1554.
27. Packman CH. Hemolytic anemia due to warm autoantibodies. *Blood Rev*. 2008;22(1):17-31.
28. Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. *Blood*. 2016;127(3):296-302, quiz 370.
29. Meyer O, Stahl D, Beckhove P, Huhn D, Salama A. Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type. *Br J Haematol*. 1997;98(4):860-862.
30. Coon WW. Splenectomy in the treatment of hemolytic anemia. *Arch Surg*. 1985;120(5):625-628.
31. Patel NY, Chilsen AM, Mathiason MA, Kallies KJ, Bottner WA. Outcomes and complications after splenectomy for hematologic disorders. *Am J Surg*. 2012;204(6):1014-1019, discussion 1019-1020.
32. Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. *Am J Hematol*. 1999;61(2):98-102.
33. Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. *Blood*. 2015;125(21):3223-3229.
34. Konradsen HB, Rasmussen C, Ejstrup P, Hansen JB. Antibody levels against *Streptococcus pneumoniae* and *Haemophilus influenzae* type b in a population of splenectomized individuals with varying vaccination status. *Epidemiol Infect*. 1997;119(2):167-174.
35. Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. *Blood*. 2012;119(16):3691-3697.
36. Pirofsky B. Immune haemolytic disease: the autoimmune haemolytic anaemias. *Clin Haematol*. 1975;4(1):167-180.
37. Salama A. Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review. *Transfus Med Hemother*. 2015;42(5):294-301.
38. Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. *Blood*. 2002;100(2):704-706.
39. Thabet AF, Faisal M. Pulse cyclophosphamide therapy in refractory warm autoimmune hemolytic anemia: a new perspective. *Indian J Hematol Blood Transfus*. 2014;30(4):313-318.
40. Ahn YS, Rocha R, Mylvaganam R, Garcia R, Duncan R, Harrington WJ. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. *Ann Intern Med*. 1989;111(9):723-729.
41. Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. *Br J Haematol*. 1993;83(2):343-345.
42. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. *Br J Haematol*. 2002;117(3):712-715.
43. Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. *Autoimmun Rev*. 2015;14(4):304-313.
44. Maung SW, Leahy M, O'Leary HM, et al. A multicentre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. *Br J Haematol*. 2013;163(1):118-122.
45. Carson JL, Grossman BJ, Kleinman S, et al; Clinical Transfusion Medicine Committee of the AABB. Red blood cell transfusion: a clinical practice guideline from the AABB*. *Ann Intern Med*. 2012;157(1):49-58.
46. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood*. 2008;111(12):5446-5456.
47. Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. *Leukemia*. 2016;30(2):346-350.
48. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*. 2014;370(12):1101-1110.
49. Eichhorst BF, Busch R, Hopfinger G, et al; German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. *Blood*. 2006;107(3):885-891.
50. Catovsky D, Richards S, Matutes E, et al; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. *Lancet*. 2007;370(9583):230-239.
51. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. *J Clin Oncol*. 2007;25(7):793-798.
52. Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. *J Clin Oncol*. 1998;16(5):1885-1889.
53. Hallek M, Fischer K, Fingerle-Rowson G, et al; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet*. 2010;376(9747):1164-1174.
54. Byrd JC, Hertler AA, Weiss RB, Freiman J, Kweder SL, Diehl LF. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. *Ann Oncol*. 1995;6(3):300-301.
55. Chasty RC, Myint H, Oscier DG, et al. Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA). *Leuk Lymphoma*. 1998;29(3-4):391-398.
56. Kaufman M, Limaye SA, Driscoll N, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. *Leuk Lymphoma*. 2009;50(6):892-899.
57. Vitale C, Ahn IE, Sivina M, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. *Haematologica*. 2016;101(6):e254-e258.
58. Quinquenel A, Willekens C, Dupuis J, et al. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLC/MW and GOELAMS). *Am J Hematol*. 2015;90(3):204-207.
59. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. *Leukemia*. 2002;16(10):2092-2095.
60. Byrd JC, Brown JR, O'Brien S, et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*. 2014;371(3):213-223.
61. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med*. 2014;370(11):997-1007.
62. Hillmen P, Robak T, Janssens A, et al; COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. *Lancet*. 2015;385(9980):1873-1883.
63. Chandesris MO, Schleinitz N, Ferrera V, et al. [Cold agglutinins, clinical presentation and significance; retrospective analysis of 58 patients]. *Rev Med Interne*. 2004;25(12):856-865.
64. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. *Blood*. 2013;122(7):1114-1121.
65. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. *Haematologica*. 2006;91(4):460-466.
66. Gertz MA. Cold hemolytic syndrome. *Hematology Am Soc Hematol Educ Program*. 2006;2006:19-23.
67. Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. *Leuk Lymphoma*. 2006;47(2):253-260.
68. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. *Blood*. 2004;103(8):2925-2928.
69. Dacie JV. The Haemolytic Anaemias: Congenital and Acquired. Vol 2. New York, NY: Grune & Stratton; 1960.
70. Silberstein LE, Berkman EM, Schreiber AD. Cold hemagglutinin disease associated with IgG cold-reactive antibody. *Ann Intern Med*. 1987;106(2):238-242.
71. Go RS, Serck SL, Davis JJ, et al. Long-term follow up of patients with cold agglutinin disease. *Blood*. 2005;106(11):3710.
72. Jaffe CJ, Atkinson JP, Frank MM. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. *J Clin Invest*. 1976;58(4):942-949.
73. Berentsen S, Randen U, Vågan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. *Blood*. 2010;116(17):3180-3184.
74. Berentsen S, Tjønnfjord GE, Shammam FV, et al. No response to cladribine in five patients with chronic cold agglutinin disease. *Eur J Haematol*. 2000;65(1):88-90.
75. Izumi M, Tsunemine H, Suzuki Y, et al. Successful treatment of refractory cold hemagglutinin in MYD88 L265P mutation-negative Waldenström's macroglobulinemia with bortezomib. *Int J Hematol*. 2015;102(2):238-243.
76. Röth A, Hüttmann A, Rother RP, Dührsen U, Philipp T. Long-term efficacy of the complement

- inhibitor eculizumab in cold agglutinin disease. *Blood*. 2009;113(16):3885-3886.
77. Shapiro R, Chin-Yee I, Lam S. Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity. *Clin Case Rep*. 2015;3(11):942-944.
78. Gueli A, Gottardi D, Hu H, Ricca I, De Crescenzo A, Tarella C. Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report. *Blood Transfus*. 2013;11(2):311-314.
79. Vassou A, Alymara V, Chaidos A, Bourantas KL. Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease. *Int J Hematol*. 2005;81(5):421-423.
80. Bhattacharyya J, Mihara K, Takihara Y, Kimura A. Successful treatment of IgM-monoclonal gammopathy of undetermined significance associated with cryoglobulinemia and cold agglutinin disease with immunochemotherapy with rituximab, fludarabine, and cyclophosphamide. *Ann Hematol*. 2012;91(5):797-799.
81. Garratty G. Immune hemolytic anemia associated with negative routine serology. *Semin Hematol*. 2005;42(3):156-164.
82. Segel GB, Lichtman MA. Direct antiglobulin ("Coombs") test-negative autoimmune hemolytic anemia: a review. *Blood Cells Mol Dis*. 2014;52(4):152-160.
83. Karafin MS, Denomme GA, Schanen M, Gottschall JL. Clinical and reference lab characteristics of patients with suspected direct antiglobulin test (DAT)-negative immune hemolytic anemia. *Immunohematology*. 2015;31(3):108-115.
84. Leger RM, Co A, Hunt P, Garrity G. Attempts to support an immune etiology in 800 patients with direct antiglobulin test-negative hemolytic anemia. *Immunohematology*. 2010;26(4):156-160.
85. Kamesaki T, Toyotsuji T, Kajii E. Characterization of direct antiglobulin test-negative autoimmune hemolytic anemia: a study of 154 cases. *Am J Hematol*. 2013;88(2):93-96.
86. Zuercher AW, Spirig R, Baz Morelli A, Käsermann F. IVIG in autoimmune disease - Potential next generation biologics. *Autoimmun Rev*. 2016;15(8):781-785.



blood[®]

2017 129: 2971-2979

doi:10.1182/blood-2016-11-693689 originally published
online March 30, 2017

How I treat autoimmune hemolytic anemia

Ronald S. Go, Jeffrey L. Winters and Neil E. Kay

Updated information and services can be found at:

<http://www.bloodjournal.org/content/129/22/2971.full.html>

Articles on similar topics can be found in the following Blood collections

[Free Research Articles](#) (5405 articles)

[How I Treat](#) (240 articles)

[Red Cells, Iron, and Erythropoiesis](#) (951 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:

<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://www.bloodjournal.org/site/subscriptions/index.xhtml>